Calithera Biosciences Appoints William D. Waddill Chief Financial Officer

  Calithera Biosciences Appoints William D. Waddill Chief Financial Officer

PR Newswire

SOUTH SAN FRANCISCO, Calif., March 25, 2014

SOUTH SAN FRANCISCO, Calif., March 25, 2014 /PRNewswire/ --Calithera
Biosciences, a clinical-stage biotechnology company focused on the development
of novel cancer therapeutics, today announced the appointment of William D.
Waddill as Senior Vice President, Chief Financial Officer, effective April 1,
2014. As CFO, Mr. Waddill will provide input on corporate strategy and
oversee all corporate financial matters, including financial planning and
reporting, as well as investor relations. He will report directly to Susan
Molineaux, PhD, President and Chief Executive Officer.

"Will's extensive management experience and accomplishments, especially in the
growth and maturation of life science companies, provide Calithera with
exceptional financial and business leadership," said Dr. Molineaux. "He
brings valuable perspective to our team, with first-hand and recent experience
contributing to the formation of strategic alliances and guiding companies
through diverse fundraising options, including an initial public offering. We
are privileged to have him join our executive team as our first product
candidate advances through Phase 1 clinical studies."

A life science industry veteran and active member of the biotechnology
industry, Mr. Waddill joins Calithera from OncoMed Pharmaceuticals where he
served as Senior Vice President, CFO since 2007 responsible for all corporate
financial matters, most notably the successfully completed $94 million Initial
Public Offering in July 2013, private equity financing of $126 million in
December 2008, and three collaborations valued at $6.1 billion. Prior to
OncoMed, Mr. Waddill was Senior Vice President, CFO, at Ilypsa, where he was
the finance lead for the $420 million acquisition by Amgen in 2007. Before
joining Ilypsa, Mr. Waddill served as the founder and principal at Square One
Finance, a financial consulting business, managing the finances of 33 start-up
biotechnology companies, including eight that became public and six that were
acquired. Mr. Waddill serves on the board of the Association of Bioscience
Financial Officers and Chaired their 2014 National Conference. He also served
as the Chairman of the Biotechnology Industry Organization (BIO) Business
Solutions Advisory Board and Finance and Tax Committee. He received a BS in
accounting from the University of Illinois, Chicago, and certification as a
public accountant (inactive) after working at PriceWaterhouseCoopers and
Deloitte in Boston.

"This is an exciting time to be joining Calithera, with lead anti-cancer
compound CB-839 progressing in the clinic and having demonstrated promise as a
product that may target tumor cell metabolism in hematologic and solid tumor
types," said Mr. Waddill. "I look forward to joining Susan and her
high-caliber team in helping chart the course of the company to support its
future success."

About Calithera Biosciences

Calithera Biosciences, Inc. is a clinical-stage company focused on the
discovery, development and commercialization of first-in-class small molecule
oncology therapeutics. The company is building a pipeline of targeted
anti-cancer compounds that inhibit pathways critical to tumor growth and
survival. Calithera's lead clinical candidate, CB-839, blocks glutaminase, an
enzyme critical to tumor metabolism, and is currently being tested in patients
with advanced solid and hematological cancers. Calithera Biosciences is
headquartered in South San Francisco. For more information about Calithera
Biosciences, please

SOURCE Calithera Biosciences

Contact: Susan M. Molineaux, PhD, President and CEO, Calithera Biosciences,, BCC Partners, Karen L. Bergman or Michelle Corral,
650.575.1509 or 415.794.8662
Press spacebar to pause and continue. Press esc to stop.